This trial is evaluating whether Structured External Memory Aid Treatment (SEMAT) will improve 2 primary outcomes and 9 secondary outcomes in patients with Cognitive Decline. Measurement will happen over the course of Immediately post-treatment to 8-weeks later.
This trial requires 65 total participants across 2 different treatment groups
This trial involves 2 different treatments. Structured External Memory Aid Treatment (SEMAT) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
The process that leads to a decline in cognitive competence can have a variety of causes including age, age-related changes such as hearing loss, and hormonal fluctuations which, while important, do not contribute significantly to cognitive decline.
The cognitive signs of ageing can be seen in cognitive functioning. Memory and spatial orientation are most at risk. In addition the signs of ageing can lead to difficulty with the executive function of cognition. It is also often the case that dementia can coexist with the signs of ageing, hence the need for early detection and intervention. In addition, these signs may take the form of deterioration (for example, difficulty concentrating, memory problems, trouble thinking, loss of insight, and difficulty speaking).\n
Older adults with mild to moderate cognitive impairment represent a group with substantial, yet manageable, health risks. Treatments that target these problems, such as improving walking abilities, can significantly reduce the risks of falls, hospitalizations, and institutionalization.
Although it is difficult to determine the cause of the development of cognitive decline in late life, it is often accompanied by a decline in some cognitive domains. A large body of research has linked the development of cognitive decline with functional health status. Although cognitive decline may be a part of successful aging, it has also been well documented as an independent predictor of adverse health outcomes in the elderly, including all-cause mortality, cardiovascular disease, and dementia. The effects of cognitive deterioration may not be totally limited to the brain, and therefore the need to better understand the mechanisms underlying the relationship between cognition and functional health should be emphasized by both researchers and clinicians. Furthermore, the detection and management of dementia are very important and should be considered a priority for intervention.
The most common treatment for cognitive impairment, regardless of the cause of the impairment, is medication, particularly for mild cognitive impairment. Of these, antidepressants and other medications may also be effective for Alzheimer's disease and other dementias. Cognitive impairment and dementia are increasingly treated with nonpharmacological approaches, including the exercise, enriched environment, and music intervention programs. The role of psychotherapy has yet to be explored.
Approximately 32 million Americans have at least one cognitive decline event each year. The prevalence of cognitive decline increases with age. The occurrence of one or more cognitive decline events by year 5 predicted future declines in cognition beyond age- and education-based effects. Older women have a lower risk for cognitive decline than older men.
Results from a recent paper highlighted the need for a comprehensive dementia screening strategy in order to make the most of the opportunities for research, as well as the risk and burden to the individual. Although most people aged 80+ have not reported memory changes, this study demonstrates that trials for dementia might offer an attractive and economically advantageous alternative to community-based support.
Results from a recent clinical trial suggests not only the potential benefits of treatment but also a wider range of cognitive complaints that could be amenable to a specific treatment--the use of an external memory aid--and that the presence or absence of the memory aid can influence the effects of treatment on cognition.
A great deal of research has shown that cognitive decline does not exist and is not related to normal aging. There is therefore no evidence of an association between chronic fatigue and cognitive impairment.
Clinical trials have been conducted involving [semat]-related methods and devices such as [semat-guided training (STG) and visual-spatial attention training (VSTG)(] and [semat-based cognitive training (CB). The objective n of these clinical studies was to determine whether or not external memory aids (i.e. semat) can be used as a treatment method by itself. However, semat is not usually considered semat-friendly by medical professionals but rather semat is only used to evaluate semat-related strategies such as STG/VSTG.
A high effect size was found and the results point to an important clinical effect. Therefore, the SEM-Program is a promising treatment modality that deserves further consideration.
Results from a recent clinical trial provides only a preliminary estimation of the size of the association between a cognitive complaint and change in PAD-C scores. There are limitations in this study in terms of the generalizability of the findings to the wider stroke population and the limitations of this cross-sectional study design.